Johnson & Johnson's Darzalex Q2 sales surpass projections

Coming in over analysts’ expectations, the US-based pharmaceutical giant has booked sales of Darzalex, a cancer drug developed by Genmab, for the year’s second quarter.
by marketwire, translated by daniel pedersen

Tuesday, Johnson & Johnson publicized its financial figures for the second quarter, and among the US-based firm’s different revenue streams is cancer drug Darzalex, developed by J&J subsidiary Janssen on license from Danish biotech firm Genmab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading